Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis

NCT01892436 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: Secukinumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals